Cov khoom

Bromelain (BR) yog ib qho cysteine ​​protease nrog inhibitory cuam tshuam rau txoj hnyuv thiab o.Txawm li cas los xij, nws cov teebmeem ntawm txoj hnyuv motility tsis tau tshawb nrhiav ntau.Yog li, peb tau tshawb xyuas cov txiaj ntsig ntawm cov nroj tsuag no los ntawm cov kab mob hauv plab hnyuv thiab kev hloov hauv cov nas.Contractility hauv vitro raug soj ntsuam los ntawm stimulating nas cais ileum, hauv ib lub cev da dej, nrog acetylcholine, barium chloride, los yog hluav taws xob stimulation.Motility nyob rau hauv vivo tau ntsuas los ntawm kev ntsuam xyuas qhov kev faib tawm ntawm qhov ncauj ntawm qhov ncauj fluorescent marker raws txoj hnyuv me.Transit kuj raug soj ntsuam hauv cov xeev pathophysiologic induced los ntawm cov pro-inflammatory compound croton roj los yog los ntawm cov diabetogenic tus neeg saib xyuas streptozotocin.Bromelain inhibited cov contractions induced los ntawm txawv spasmogenic tebchaw nyob rau hauv tus nas ileum nrog zoo li potency.Cov nyhuv antispasmodic raug txo los yog tawm tsam los ntawm proteolytic enzyme inhibitor, gabexate (15 × 10 (-6) mol L(-1)), protease-activated r eceptor-2 (PAR-2) antagonist, N(1) -3. -methylbutyryl-N(4) -6-aminohexanoyl-piperazine (10(-4) mol L(-1)), phospholipase C (PLC) inhibitor, neomycin (3 × 10 (-3) mol L(-1)) , thiab phosphodiesterase 4 (PDE4) inhibitor, rolipram (10 (-6) mol L(-1)).Nyob rau hauv vivo, BR nyiam inhibit motility nyob rau hauv pathophysiologic xeev nyob rau hauv ib tug PAR-2-antagonist-sensitive yam.Peb cov ntaub ntawv qhia tias BR inhibits plab hnyuv motility - nyiam nyob rau hauv pathophysiologic tej yam kev mob - nrog ib tug mechanism tejzaum nws muaj feem xyuam rau daim nyias nyias PAR-2 ​​thiab PLC thiab PDE4 li intracellular. teeb liab.Bromelain tuaj yeem yog cov khoom siv lead ua rau kev txhim kho cov tshuaj tshiab, tuaj yeem ua rau lub plab zom mov hauv qhov mob thiab mob ntshav qab zib.